Company Performance - Badger Meter (BMI) closed at $209.78, reflecting a +1.49% change from the previous day, outperforming the S&P 500 which gained 0.12% [1] - Over the past month, shares of Badger Meter have decreased by 10.27%, underperforming the Computer and Technology sector's loss of 3.73% and the S&P 500's loss of 3.45% [2] Earnings Expectations - Badger Meter is expected to release its earnings on January 31, 2025, with an anticipated EPS of $1, representing a 19.05% increase year-over-year [3] - The consensus estimate for revenue is $198.92 million, indicating a 9.04% increase compared to the same quarter of the previous year [3] Analyst Projections - Investors should monitor recent shifts in analyst projections for Badger Meter, as positive estimate revisions can indicate optimism about the company's business outlook [4] - Changes in estimates are correlated with near-term stock prices, which is utilized in the Zacks Rank system to provide a rating [5] Zacks Rank and Valuation - Badger Meter currently holds a Zacks Rank of 2 (Buy), with the Zacks Rank system showing an average annual return of +25% for 1 ranked stocks since 1988 [6] - The company has a Forward P/E ratio of 43.59, which is a premium compared to the industry average Forward P/E of 22.13 [7] - Badger Meter's PEG ratio is 2.29, aligning with the industry average PEG ratio of 2.29 [7] Industry Context - The Instruments - Control industry, part of the Computer and Technology sector, has a Zacks Industry Rank of 177, placing it in the bottom 30% of over 250 industries [8] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating the relative weakness of the current industry ranking [8]

Following my previous publication on Badger Meter (NYSE: BMI ) the stock is another +4% and now some serious decisions must be made.Equity strategist + Co-PM Global Equities [Bernard Holdings]. Objective view on the directional bias of markets. Technical expertise bridges the complex relationships between value drivers, capital flows and price action. Partners are represented over the cross-section of financial markets, from speculators, hedgers, long-term traders and the public. Research covers investment ...

Badger Meter (BMI) closed the most recent trading day at $213.44, moving +0.03% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.55%. Elsewhere, the Dow lost 0.06%, while the tech-heavy Nasdaq added 1.24%.The investment community will be closely monitoring the performance of Badger Meter in its forthcoming earnings report. The company is predicted to post an EPS of $1, indicating a 19.05% growth compared to the equivalent quarter last year. In the meantime, ...

Badger Meter (BMI) stock has gained 39.5% in the past year outpacing the S&P 500 composite and the sub-industry’s 26.4% and 0.5% growth, respectively. It has also outperformed the broader Zacks Computer and Technology sector’s growth of 34.2%.Price PerformanceImage Source: Zacks Investment ResearchThe stock was down 2.1% on Friday and closed trading at $215.45, down 10% from its 52-week high of $239.11.Does this pullback indicate a buying opportunity? Let us dive into BMI’s prospects and determine your port ...

In the latest market close, Badger Meter (BMI) reached $220, with a +1.44% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 1.1% for the day. On the other hand, the Dow registered a gain of 0.91%, and the technology-centric Nasdaq increased by 1.35%.The the stock of manufacturer of products that measure gas and water flow has fallen by 1.53% in the past month, lagging the Computer and Technology sector's gain of 5.09% and the S&P 500's gain of 0.22%.Market pa ...

Core Viewpoint - Badger Meter (BMI) has shown strong stock performance, with a 5% increase over the past month and a 49.4% gain since the beginning of the year, outperforming both the Zacks Computer and Technology sector and the Zacks Instruments - Control industry [1][2]. Financial Performance - Badger Meter reported an EPS of $1.08 in its latest earnings report, exceeding the consensus estimate of $1.02, although it missed the revenue estimate by 0.28% [2]. - For the current fiscal year, the company is projected to achieve earnings of $4.19 per share on revenues of $820.32 million, reflecting a 33.44% increase in EPS and a 16.59% increase in revenues [3]. - The next fiscal year forecasts earnings of $4.74 per share on revenues of $887.29 million, indicating year-over-year changes of 13.22% in EPS and 8.16% in revenues [3]. Valuation Metrics - Badger Meter's current valuation metrics indicate a premium, trading at 55.1X current fiscal year EPS estimates compared to the peer industry average of 25.2X, and at 56.1X on a trailing cash flow basis versus an average of 21.8X for peers [7]. - The stock has a PEG ratio of 2.9, which does not place it among the top value stocks [7]. Zacks Rank and Style Scores - Badger Meter holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8]. - The stock has a Value Score of C, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of B [6][9].

In the latest trading session, Badger Meter (BMI) closed at $220.56, marking a +1.72% move from the previous day. This change outpaced the S&P 500's 0.25% gain on the day. At the same time, the Dow lost 0.29%, and the tech-heavy Nasdaq gained 0.97%.The manufacturer of products that measure gas and water flow's shares have seen an increase of 7.35% over the last month, surpassing the Computer and Technology sector's gain of 0.06% and the S&P 500's gain of 3.51%.Analysts and investors alike will be keeping a ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zack ...

Core Viewpoint - Badger Meter (BMI) has experienced a significant stock price increase of 39.8% year to date, outperforming both the S&P 500 and its sub-industry growth rates, raising questions about the sustainability of this rally [1] Group 1: Demand and Revenue Growth - There is a robust demand for digital smart water solutions, driven by challenges in the water industry, leading to increased adoption of BMI's smart water solutions, including mechanical and E-Series Ultrasonic meters, ORION Cellular endpoints, and BEACON Software-as-a-Service (SaaS) [4] - SaaS revenues grew approximately 35% in the third quarter, reflecting a rising customer reliance on insights from BEACON digital solutions, supported by favorable macroeconomic factors and a strong opportunity funnel [5] - Utility water sales increased by 14% in the third quarter, attributed to the adoption of the BlueEdge framework, which offers customizable solutions for the entire water cycle [6] Group 2: Profitability and Financial Health - BMI's gross profit reached $83.9 million in the third quarter, marking a 15.3% year-over-year increase, with a gross margin of 40.2%, up 110 basis points from the previous year [8] - The company maintains a debt-free balance sheet with $259 million in cash and cash equivalents as of September 30, 2024, and reported a record quarterly free cash flow of $42 million, indicating strong earnings and working capital management [10] - BMI announced a 26% increase in its quarterly dividend to 34 cents per share, marking 32 consecutive years of dividend increases, with a payout ratio of 0.34 [11] Group 3: Challenges and Market Outlook - Sales of flow instrumentation products are facing challenges due to declines in certain de-emphasized applications globally, and hurricane recovery activities may delay utility projects in the Southeast U.S., introducing uncertainty [12] - The company anticipates fewer customer operating days in the fourth quarter due to the holiday season, which may lead to reduced sales growth, projecting high single-digit sales growth rates moving forward [13] - Rising operating expenses, particularly in selling, engineering, and administration, increased to $43.3 million in the third quarter, which could pressure margins if not offset by revenue growth [14] Group 4: Valuation Concerns - BMI is currently trading at a high valuation, with a forward 12-month price-to-earnings ratio of 46.59, significantly above the industry average of 19.72, raising concerns about its investment attractiveness [15]

Core Insights - Rhythm Pharmaceuticals presented new real-world data indicating significant reductions in body mass index (BMI) and improvements in hunger scores among adult patients with acquired hypothalamic obesity treated with setmelanotide [1][2][3] Group 1: Real-World Data Analysis - In a study of eight adult patients, mean BMI decreased by 5.6% after one month, 12.8% after three months, and 21.3% after six months of setmelanotide treatment [2] - All patients experienced a weight reduction of 5% or more after three months, and all showed reductions in multiple hunger score categories [2] - No new safety signals were reported during the treatment period [2] Group 2: Phase 2 and Phase 3 Trial Results - Phase 2 trial data showed a mean BMI reduction of 12.4% in patients with rare MC4R pathway diseases after 40 weeks of continuous setmelanotide therapy [1][5] - In the Phase 3 VENTURE trial, pediatric patients aged 2 to <6 years achieved a mean BMI reduction of 23.8% after 18 months of treatment [1][7] - The Phase 2 trial demonstrated a greater reduction in fat mass (29.6%) compared to lean muscle mass (7.7%) after 12 months of treatment [4] Group 3: Genetic Testing Insights - Analysis of over 43,000 genetic samples revealed a 7.39% positivity rate for likely pathogenic variants associated with early-onset obesity [9][10] - Family history of genetic disease was significantly linked to positive test results, and early-onset hyperphagia was more common in individuals with positive genetic findings [10] Group 4: Company Overview - Rhythm Pharmaceuticals focuses on developing treatments for rare neuroendocrine diseases, with setmelanotide being its lead asset approved for chronic weight management in specific obesity cases [12][13] - The company is advancing a broad clinical development program for setmelanotide and other investigational MC4R agonists [12]